You just read:

Daiichi Sankyo Initiates Pivotal Phase 3 Trial of [Fam-] Trastuzumab Deruxtecan (DS-8201) in HER2 Low Metastatic Breast Cancer

News provided by

Daiichi Sankyo Company, Limited

14 Jan, 2019, 13:00 GMT